

DiagnaMed Strengthening Intellectual Property Support for CERVAI[™] Brain Health AI Solution


Potential \$150,000 in non-dilutive funding support through IPON and IP Assist Programs

TORONTO, March 14, 2024 -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, is pleased to announce it has strengthened support for its intellectual property portfolio by being a client of Intellectual Property Ontario ("IPON") Partner Program and the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") IP Assist program, which combined, offers a potential of \$150,000 in non-dilutive funding. The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.

Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: "We have made significant technical and operating progress with CERVAI[™], our novel brain health AI solution, and we are pleased to strengthen support of our intellectual property for commercialization with a potential \$150,000 non-dilutive funding from IPON and IP Assist programs. As part of our global commercialization plans for CERVAI[™], we continue to invest in R&D and expand our intellectual property portfolio through patents, copyrights, trademarks and trade secrets."

With the IPON Partner Program, DiagnaMed can receive up to \$35,000 in initial funding, with a further total grant of \$100,000 for intellectual property protection and commercialization services. IPON works with innovators, businesses, and researchers to provide access to expert IP education, financial support, and mentorship to help maximize the value of IP, strengthen their capacity to grow, compete in the market, and enhance research and commercialization outcomes.

DiagnaMed has completed IP Assist Level 1 with the IP Assist program and is eligible to receive up to \$50,000 for expert IP services. The NRC IRAP provides comprehensive advisory services and funding to help accelerate the growth of Canadian small and medium-sized businesses ("SMEs") and has established the IP Assist program that offers a range of targeted IP services in support of companies commercial goals and safeguarding innovations. The main goals of IP Assist are to help SMEs increase their IP awareness (level 1), develop an IP strategy (level 2) and carry out the actions needed to implement their IP strategy (level 3).



About CERVAI[™] Brain Health AI

CERVAI[™] is a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Based on research and development at Drexel University and the University of Miami, CERVAI[™] combines a Brain Age [™] Estimation and Brain Health Assessment tool with the aim to 'raise a red flag' for potential brain health issues. CERVAI[™] can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram ("EEG") headset and calculating the data with a proprietary machine-learning model. In addition, CERVAI[™] can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is an artificial intelligence digital healthcare company focused on commercializing CERVAI[™], a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit <u>DiagnaMed.com</u>.

For more information, please contact:

Fabio Chianelli Chairman and CEO DiagnaMed Holdings Corp. Tel: 416-800-2684 Email: <u>info@diagnamed.com</u> Website: <u>www.diagnamed.com</u>

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forwardlooking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three months ended December 31, 2023 ("MD&A"), dated February 29, 2024, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7a0e25fe-3e27-4326-bd8b-42a2d3d72633